Financing and going-concern risk
The company must raise additional capital to fund R&D, trials, and commercialization efforts.
- Scope
- Corporate funding and operating runway
- Materiality
- high
Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is a U.S.-based biotechnology company focused on developing engineered cell and gene therapies. Its work centers on ex vivo and in vivo cell engineering platforms designed to create medicines for diseases such as type 1 diabetes, oncology, and B cell mediated autoimmune disorders.
1.89
1.89
| % | |
|---|---|
| Ex vivo cell engineering | 35% Engineered cells modified outside the body and then administered as therapies. |
| In vivo cell engineering | 30% Therapies and delivery systems intended to modify cells directly inside the body. |
| Hypoimmune technologies | 15% Platform technologies aimed at reducing immune rejection of engineered cells. |
| Fusogen / fusosome programs | 10% Cell-targeting delivery programs based on licensed fusogen technology. |
| Preclinical and clinical pipeline | 10% Product candidates and supporting development work across therapeutic areas. |
Sana does not sell commercial products today; its direct counterparties are primarily research institutions, licensors,...
- Technology licensors and research partnersprimary
Universities and biotech partners that provide licensed platform technologies and IP used to build Sana's cell engineering programs.
- CDMOs and contract research providersprimary
External manufacturing and research organizations that produce clinical material and run parts of development programs.
- Clinical investigators and trial sitesprimary
Hospitals and research centers that enroll patients and generate clinical data for product candidates.
- Future specialty healthcare providersemerging
Physicians and treatment centers that would administer approved cell and gene therapies.
- Future payors and reimbursement systemsemerging
Commercial and government payors that would determine coverage and access for approved therapies.
Sana is headquartered in the United States and operates as a U.S.-based development-stage biotechnology company...
- •Headquartered in the United States
- •Core development and corporate functions are U.S.-based
- •Licensed patent territory covers countries where rights are filed
- •Clinical and manufacturing partners may be located globally
- •Regulatory exposure spans U.S. and foreign health authorities
Sana's strategy is to build engineered cell medicines by combining acquired and in-licensed technologies into ex vivo...
01
Advance platform-based product candidatesshort-term
The company needs clinical proof that its engineered cell approaches can become approvable medicines.
02
Strengthen manufacturing capabilitiesmedium-term
Cell therapies require reliable clinical and future commercial supply, often through specialized external manufacturing.
03
Expand and defend intellectual propertymedium-term
The platform depends on licensed and proprietary technologies that must remain protected to support differentiation.
04
Secure external funding and strategic arrangementsshort-term
Development-stage biotech requires ongoing capital to fund trials, manufacturing, and regulatory work.
Sana faces the typical risks of a development-stage cell and gene therapy company: clinical failure, regulatory...
Clinical development failure
Product candidates may not meet FDA or foreign regulator requirements for safety and efficacy.
- Scope
- Ex vivo and in vivo programs across multiple indications
- Materiality
- high
Manufacturing and supply chain disruption
Cell therapy manufacturing is complex and depends on specialized materials, processes, and third parties.
- Scope
- Clinical supply and future commercial supply
- Materiality
- high
Third-party dependence
The company relies on CDMOs, CROs, licensors, and research partners to execute core development activities.
- Scope
- Manufacturing, trials, and technology access
- Materiality
- high
Intellectual property and licensing risk
Programs depend on licensed technologies and patent protection that could be challenged or restricted.
- Scope
- UCLA fusogen license, Harvard/UCSF hypoimmune technology, Beam license
- Materiality
- high
Research and development accruals
Operating expense volatility
Asset acquisition and IPR&D accounting
Large one-time R&D charges
Goodwill and intangible impairment
Non-cash impairment charges
License milestones and royalties
R&D expense and liquidity
: 29.4.2026